; mAb for RIT and Imaging in Pancreatic Cancer
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

mAb for RIT and Imaging in Pancreatic Cancer

VIEWS: 5 PAGES: 1

The research, in nude mice bearing caPanl human pancreatic cancer xenografts, included biodistribution studies and nuclear imaging of the radiolabeled TFlO and/or a TF10-pretargeted hapten-peptide (IMP-288). ^sup 125^I-labeled TFlO was found to clear rapidly from the blood, with levels decreasing to 1% injected dose per gram (%ID/g) by 16 h, at which time tumor uptake was 3.47 0.66 %ID/g, with no accumulation in normal tissue. ^sup 111^In-labeled IMP-288 was administered 16 h after the TF10.

More Info
To top